SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL). (12th June 2019) - Metzger, M.; Mauz‐Körholz, C.; Flerlage, J.; Bartelt, J.; Billett, A.; Choi, J.K.; Ehrhardt, M.; Georgi, T.; Hasenclever, D.; Wang, F.; Zhang, H.; Kaste, S.C.; et al.